文献速递免疫规划传染病防控与疫情报告

舌下接种BCG疫苗可诱导分枝杆菌保护性免疫

Induction of mycobacterial protective immunity by sublingual BCG vaccination.
PubMed 文献 · Vaccine · 2019-07-19

皮内接种BCG可预防婴幼儿严重急性结核病,但不能预防慢性感染或肺结核。该临床前研究在小鼠中测试舌下BCG接种,发现其可诱导持久的分枝杆菌特异性T细胞应答,并对气溶胶攻击的强毒结核分枝杆菌产生显著且持久的保护。

要点

  • 舌下BCG诱导的分枝杆菌特异性T细胞应答可持续16周。
  • 舌下BCG小鼠对气溶胶强毒结核分枝杆菌攻击显著保护(P < 0.0001)。
  • 保护持久16周,肺和脾CFU降低>1 log(P < 0.0001和P < 0.0028)。

核心结论

  • 舌下BCG接种可诱导持久的分枝杆菌特异性T细胞应答,并对气溶胶强毒结核分枝杆菌攻击产生显著且持久的保护。

研究设计与样本

  • 小鼠临床前疫苗测试:比较舌下、鼻内和皮下BCG接种的免疫应答,并进行气溶胶强毒结核分枝杆菌攻击保护实验。

主要发现

  • 舌下BCG诱导的分枝杆菌特异性T细胞应答在免疫后16周仍持续存在。
  • 舌下、鼻内和皮下BCG接种诱导的T细胞应答强度相似。
  • 舌下BCG后血清分枝杆菌特异性抗体应答和BCG全身回收低于全身BCG免疫。
  • 舌下BCG小鼠对气溶胶强毒结核分枝杆菌攻击显著保护(P < 0.0001 vs 未接种小鼠)。
  • 保护持久16周,肺和脾CFU较未接种攻击小鼠降低>1 log(P < 0.0001和P < 0.0028)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) remains a tremendous global health problem, with 1/4 of the world's population infected and causing > 1 million deaths annually. Intradermal Bacillus Calmette-Guérin (BCG) vaccine given during infancy protects against severe forms of acute disease but does not prevent chronic infection or development of pulmonary TB. TB vaccine mucosal targeting potentially could induce mucosal resident immune cells with increased protective capacity against pulmonary infection and disease. Sublingual (SL) administration of vaccines may be an optimal mucosal delivery platform based on the high absorptive capacity of this mucosal surface, the extensive lymphoid tissue, and published preclinical studies demonstrating efficacy of SL vaccination against other pathogens. To this end, we performed preliminary testing of sublingual TB vaccines. Vaccination of mice with SL BCG elicited potent mycobacteria-specific T cell responses which persisted 16 weeks post-immunization. The magnitudes of the T cell responses were similarly induced after sublingual, intranasal, and subcutaneous BCG vaccination. Interestingly, serum mycobacteria-specific antibody responses and systemic recovery of BCG post-vaccination were lower after SL BCG compared with systemic BCG immunization. However, more importantly, SL BCG vaccinated mice were significantly protected against an aerosolized virulent M. tuberculosis challenge (P < 0.0001 compared to unvaccinated mice). Furthermore, this protection was long-lived, persisting for 16 weeks with >1 log CFU reduction compared with naïve challenged mice in both lungs and spleens (P < 0.0001 and P < 0.0028, respectively). These exciting results provide strong support for further studies exploring the mechanisms of protective immunity induced by sublingual BCG vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Eickhoff CS, Blazevic A, Killoran EA, et al. Induction of mycobacterial protective immunity by sublingual BCG vaccination. Vaccine. 2019. PMID: 31331776. doi:10.1016/j.vaccine.2019.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。